Spectral AI (Spectral AI) Momentum Rank : 0 (As of Jun. 24, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Momentum Rank?

Spectral AI has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Spectral AI Momentum Rank Related Terms

Thank you for viewing the detailed overview of Spectral AI's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201

Website

https://www.spectralmd.com

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.

Executives

John Michael Dimaio	10 percent owner	6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p.	10 percent owner	2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton	director	RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b.	director	13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher	officer: Chief Scientist	6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler	officer: Chief Financial Officer	8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan	director, officer: CHIEF EXECUTIVE OFFICER	3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone	officer: GENERAL COUNSEL	1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos	officer: CHIEF OPERATING OFFICER	5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai	director	10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr.	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg	10 percent owner	73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260